Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Payables (2016 - 2025)

CytomX Therapeutics' Payables history spans 12 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Payables rose 19.58% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 19.58%, while the annual FY2025 figure was $1.3 million, 19.58% up from the prior year.
  • Payables reached $1.3 million in Q4 2025 per CTMX's latest filing, up from $646000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.2 million in Q3 2022 to a low of $227000.0 in Q2 2025.
  • Average Payables over 5 years is $1.7 million, with a median of $1.6 million recorded in 2021.
  • Peak YoY movement for Payables: surged 241.42% in 2022, then crashed 85.95% in 2025.
  • A 5-year view of Payables shows it stood at $2.8 million in 2021, then decreased by 0.32% to $2.8 million in 2022, then crashed by 48.1% to $1.5 million in 2023, then decreased by 25.38% to $1.1 million in 2024, then increased by 19.58% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Payables are $1.3 million (Q4 2025), $646000.0 (Q3 2025), and $227000.0 (Q2 2025).